Back to top
more

Regulus Therapeutics (RGLS)

(Delayed Data from NSDQ)

$2.08 USD

2.08
568,184

-0.01 (-0.48%)

Updated May 14, 2024 04:00 PM ET

After-Market: $2.07 -0.01 (-0.48%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for RGLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Regulus Therapeutics Inc. [RGLS]

Reports for Purchase

Showing records 221 - 240 ( 270 total )

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 221

08/14/2014

Industry Report

Pages: 12

LIFE SCIENCES AND HEALTH CARE - 2014 LSMAC Day 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 222

08/14/2014

Industry Report

Pages: 12

LIFE SCIENCES AND HEALTH CARE-2014 LSMAC Day 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 223

08/08/2014

Industry Report

Pages: 47

Emerging Pharmaceuticals - August and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 224

08/07/2014

Company Report

Pages: 6

Reports 2Q’14 EPS; HCV POC Data in 4Q''14

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 225

08/07/2014

Company Report

Pages: 6

Q2 Earnings, Proof of Concept Data Release in Q4, Reiterate OUTPERFORM and $19 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 226

07/18/2014

Daily Note

Pages: 5

FDA Grants Orphan Drug Designation To RG-012 for the Treatment of Alport Syndrome

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 227

07/18/2014

Daily Note

Pages: 5

FDA Grants Orphan Drug Designation To RG-012 for the Treatment of Alport Syndrome

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 228

07/02/2014

Industry Report

Pages: 48

July and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 229

06/25/2014

Daily Note

Pages: 5

Granted Patent Strengthens Company’s IP Position on microRNA Therapeutics for HCV; Reiterate OUTPERFORM and $19 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 230

06/25/2014

Daily Note

Pages: 5

Granted Patent Strengthens Company’s IP Position on microRNA Therapeutics for HCV; Reiterate OUTPERFORM and $19 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 231

06/02/2014

Daily Note

Pages: 47

June and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 232

05/30/2014

Daily Note

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 233

05/23/2014

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 26

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 234

05/21/2014

Industry Report

Pages: 47

Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 235

05/13/2014

Company Report

Pages: 28

Initiating coverage with a Market Outperform and $16 Price Target

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 75.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 236

05/13/2014

Company Report

Pages: 7

Q1 2014 Update; RG-101/HCV Inhibition Data by YE:14: Reiterate OUTPERFORM and $19 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 237

04/09/2014

Daily Note

Pages: 46

April and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 238

03/06/2014

Daily Note

Pages: 4

Announced Dosing of the First Subject in the RG-101 Phase I Study

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 239

03/06/2014

Daily Note

Pages: 4

Announced Dosing of the First Subject in the RG-101 Phase I Study

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 240

02/28/2014

Company Report

Pages: 5

Q4 Financials and Update - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party